Tae Seok Moon is a full professor at J. Craig Venter Institute, an EBRC (Engineering Biology Research Consortium) Council Member, a SynBYSS (Synthetic Biology Young Speaker Series) Chair, a founder of Moonshot Bio, an Executive Board Member of the European Federation of Biotechnology, and an editor of 10 journals, including the Editor-in-Chief of New Biotechnology and the Executive Editor of Biocatalysis and Agricultural Biotechnology. He is also the director of NSF Global Center CIRCLE consisting of 16 companies and >40 academic investigators at 18 institutes from 6 nations.

He has expertise in Systems and Synthetic Biology. He aims to solve global agricultural, environmental, manufacturing, and health problems through engineering biology. His research projects have been supported by Gates Foundation, AIChE, and 14 governmental funding agencies (31 external grants), and he has secured >$14M (>$43M for the entire teams since 7/1/2012). These projects and his prior research efforts have resulted in 104 publications (93 as the PI), 224 invited talks, 203 contributed conference presentations, and 10 patents. His achievements have also been recognized with many awards, including a Langer Prize for Innovation and Entrepreneurial Excellence (AIChE & MIT), a B&B Daniel I.C. Wang Award (Wiley & ACS), an NSF CAREER award, an ONR Young Investigator Award, a John C. Sluder Fellowship (MIT), an ILJU Foundation Award, an LG Chemical Fellowship, and the SNU President Prize.

He is deeply committed to spending the time required to promote the career development of his advisees and young researchers in the world. He has advised 115 young researchers who are diverse in race, gender, and nationality since 2012, including 22 students in other labs as a committee member, 29 undergrad researchers, 6 international Genetically Engineered Machine (iGEM) competition teams (not counted toward 115), 31 grad rotation students (excluding ones who joined his lab permanently), 18 PhD students (8 students graduated), 3 MS students (funded by him), 4 technicians, and 8 postdoctoral researchers. Among these 29 undergrad researchers, 12 students chose to pursue grad studies in STEM. Many lab members have received fellowships & awards for their research, and lab alumni are contributing to society in universities, national labs, and industries (e.g., one developed the Pfizer COVID-19 vaccine). In addition, teaching kits have been developed and distributed to more than 40 high school science teachers and hundreds of K-12 students, broadening impacts on STEM education.

He is an active member of the global community of researchers who work in the fields of chemical engineering and bioengineering. He has actively participated in organizing many international conferences as a conference co-chair or organizer. He has also served as a reviewer, the editor-in-chief (New Biotechnology), the Executive Editor (Biocatalysis and Agricultural Biotechnology), an associate editor (8 journals), or an editorial board member (7 journals) for >50 journals, including Nature/Science/Cell journals, Nucleic Acids Res., and PNAS. Notably, his global leadership efforts include 1) his activity and role at EBRC as a Council Member to provide the vision to address national and global needs through synthetic biology and 2) his service to SynBYSS as the Founding Chair to provide a weekly, virtual, and multi-year forum where a global thought leader gives an opening 5 min talk, followed by a 45 min, rising star’s talk, for >1,000 global audiences. The 417 speakers (as of Jan. 2025) include a Nobel Laureate, 22 National Academy Members, 42 funding agency directors, 20 Editors-in-chief, 11 Nature/Cell journal editors, and 199 rising stars.

Dr. Schnabl received his medical degree from the University of Freiburg in Germany. During his three-year postdoctoral research training at the Department of Medicine, Biochemistry & Biophysics at the University of North Carolina at Chapel Hill, he started to study hepatic stellate cell biology and pathophysiology of chronic liver diseases. He completed a residency in Medicine at the University Hospital in Regensburg/Germany and a Gastroenterology fellowship at Columbia University, College of Physicians and Surgeons, in New York City.

He is currently a Professor of Medicine in the Division of Gastroenterology at the University of California San Diego. He is staff physician and attending at the VA San Diego Medical Center and the UC San Diego Medical Center. He divides his time between clinical work and research. He recently became the Director of the NIH-funded San Diego Digestive Diseases Research Center (SDDRC).

The gut microbiota plays a crucial role in health and disease. We are focused on the virus component of the microbiome called the virome, and its role in human health. Our favourite group of organisms in the microbiome are the bacteriophages, viruses that infect bacteria.

We aim to elucidate the role of viruses in the healthy gut across life, leveraging data generated by the QI PEARL and MOTION studies. We are investigating the role of prophages in bacterial fitness and adaptation to the gut.

We are also heavily involved in virus taxonomy, creating a genomic framework with which to understand global viral diversity. We further aim to use newly isolated bacteriophages in the biocontrol of pathogenic bacteria in the fight against antimicrobial resistance, to improve human and environmental health.

We use a holistic approach of culture-dependent and computational methods to study viruses. Specifically, we are specialised in phage and prophage genomics and annotation, and viromics (viral metagenomics).

Dr. Hatfull is Professor of Biological Sciences at the University of Pittsburgh.  He completed his undergraduate studies in Biological Sciences at Westfield College, University of London (1975-1978) and graduate studies in Molecular Biology at the University of Edinburgh (1978-1981).  Following postdoctoral research at Yale University with Dr. Nigel Grindley (1981-1983, 1984-1988) and with Bart Barrell and Fred Sanger at MRC Cambridge (1983-1984) he joined the University of Pittsburgh in 1988.

Dr. Hatfull's research interests include the molecular genetics of the mycobacteria and their bacteriophages, with particular interests in viral diversity and evolution, genetic systems for tuberculosis, and the mechanisms of site-specific recombination. He also explores ways to integrate research priorities with science education and helps to lead the HHMI-supported PHIRE and SEA-PHAGES programs.